Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
[EN] INHIBITORS OF INFLUENZA VIRUSES REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DES VIRUS DE LA GRIPPE
申请人:VERTEX PHARMA
公开号:WO2010148197A1
公开(公告)日:2010-12-23
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
Transparente Polyamide, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung von Formkörpern
申请人:CIBA-GEIGY AG
公开号:EP0069067A2
公开(公告)日:1983-01-05
Es werden neue transparente Polyamide aus wiederkehrenden Strukturelementen der Formel I oder II
oder
beschrieben, worin R1 bis R4, m und Z die im Patentanspruch 1 angegebene Bedeutung haben und die Carbonylgruppen in 1,3-und/oder 1,4-Stellung an den Benzolring gebunden sind. Die neuen Polyamide eignen sich zur Herstellung von Formkörpern und zeichnen sich durch gute thermoplastische Verarbeitbarkeit, geringe Wasseraufnahme, hohe Hydrolysebeständigkeit und gute Dimensionsstabilität unter dem Einfluss von Feuchtigkeit aus.
新型透明聚酰胺是由式 I 或式 II 的重复结构单元生产的
或
其中 R1 至 R4、m 和 Z 如权利要求 1 所定义,羰基以 1,3 位和/或 1,4 位键合在苯环上。新型聚酰胺适用于生产模塑制品,具有良好的热塑性加工性能、低吸水性、高抗水解性以及在湿气影响下良好的尺寸稳定性。
Hydrogenation of single ring aromatic diamines
申请人:AIR PRODUCTS AND CHEMICALS, INC.
公开号:EP1329446A2
公开(公告)日:2003-07-23
This invention relates to an improved process for the preparation of cyclohexylamines wherein an aromatic amine is contacted with hydrogen in the presence of a hydrogenation catalyst. The improvement resides in utilizing a hydrogenation catalyst comprised of rhodium metal, utilizing a dialkyl ether solvent, and effecting delay addition of the aromatic diamine to the reaction medium.